EU/3/20/2320
Table of contents
About
On 21 August 2020, orphan designation EU/3/20/2320 was granted by the European Commission to CambPharma Solutions (CY) Limited, Cyprus, for copper histidinate (also known as CUTX-101) for the treatment of Menkes disease.
Key facts
Active substance |
Copper histidinate
|
Disease / condition |
Treatment of Menkes disease
|
Date of first decision |
21/08/2020
|
Outcome |
Positive
|
EU designation number |
EU/3/20/2320
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
CambPharma Solutions (CY) Limited
D. Vrachimis Building
Agiou Athanasiou 59
Agios Athanasios, Limassol 4102
Cyrpus
Tel. +441480465755
E-mail: pallavshah@cambreg.co.uk
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.